Mutation-specific Therapy for the Long QT Syndrome
clinical trial
Press Enter · cited answer in seconds
0 sources
Summary
Mutation-specific Therapy for the Long QT Syndrome is a clinical trial[1].
Key Facts
- Mutation-specific Therapy for the Long QT Syndrome is in the country of Italy[2].
- Mutation-specific Therapy for the Long QT Syndrome's instance of is recorded as clinical trial[3].
- Mutation-specific Therapy for the Long QT Syndrome's start time is recorded as +2021-06-15T00:00:00Z[4].
- Mutation-specific Therapy for the Long QT Syndrome's end time is recorded as +2023-11-15T00:00:00Z[5].
- Mutation-specific Therapy for the Long QT Syndrome's main subject is recorded as long QT syndrome[6].
- Mutation-specific Therapy for the Long QT Syndrome's number of participants is recorded as {'unit': '1', 'amount': '+20'}[7].
- Mutation-specific Therapy for the Long QT Syndrome's title is recorded as Mutation-specific Therapy for the Long QT Syndrome[8].
- Mutation-specific Therapy for the Long QT Syndrome's short name is recorded as MAST2[9].
- Mutation-specific Therapy for the Long QT Syndrome's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}[10].
- Mutation-specific Therapy for the Long QT Syndrome's ClinicalTrials.gov ID is recorded as NCT04581408[11].
- Mutation-specific Therapy for the Long QT Syndrome's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+65'}[12].
- Mutation-specific Therapy for the Long QT Syndrome's research intervention is recorded as ivacaftor[13].
- Mutation-specific Therapy for the Long QT Syndrome's research intervention is recorded as chloride channel agonist[14].
- Mutation-specific Therapy for the Long QT Syndrome's research intervention is recorded as membrane transport modulator[15].
- Mutation-specific Therapy for the Long QT Syndrome's research intervention is recorded as mechanism of action[16].
- Mutation-specific Therapy for the Long QT Syndrome's clinical trial phase is recorded as phase II clinical trial[17].
- Mutation-specific Therapy for the Long QT Syndrome's research subject recruitment status is recorded as recruiting[18].
- Mutation-specific Therapy for the Long QT Syndrome's study type is recorded as interventional study[19].